AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26088663 — intervention group
Group type: COMPARATOR
Intervention: Community-intervention-as-usual (COM)
Number of subjects: 39
Study 23574290 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-relaxation training including progressive muscle relaxation and meditation based on sleep hygiene education
Number of subjects: 80
Study 23574290 — intervention group
Group type: COMPARATOR
Intervention: Sleep hygiene education only
Number of subjects: 80
Study 21542426 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal toothpaste (Sudantha)
Number of subjects: 60
Study 21542426 — intervention group
Group type: COMPARATOR
Intervention: Placebo toothpaste
Number of subjects: 60
Study 19339805 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidelines group (ARIA guidelines with ebastine as oral antihistamine)
Number of subjects: 839
Study 19339805 — intervention group
Group type: COMPARATOR
Intervention: Free-choice treatment group
Number of subjects: 839
Study 16764547 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity functional exercise program
Number of subjects: 191
Study 16764547 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-enriched energy supplement
Number of subjects: 191
Study 16764547 — intervention group
Group type: COMPARATOR
Intervention: Control activity
Number of subjects: 191
Study 15153734 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen A (3 instillations at 8-hourly intervals in 1 day)
Number of subjects: 47
Study 15153734 — intervention group
Group type: COMPARATOR
Intervention: Regimen B (9 instillations at 8-hourly intervals in 3 days)
Number of subjects: 47
Study 11421903 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebastine 20 mg once daily for 7 days
Number of subjects: 23
Study 11421903 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 11421903 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebastine 20 mg
Number of subjects: 23
Study 9416721 — intervention group
Group type: COMPARATOR
Intervention: No volume loading
Number of subjects: 24
Study 9416721 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume loading of 15 ml/kg lactated Ringer's solution
Number of subjects: 24
Study 9416721 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of etilefrine
Number of subjects: 24
Study 9416721 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 24
Study 8495702 — intervention group
Group type: EXPERIMENTAL
Intervention: tetracycline
Number of subjects: 50
Study 8495702 — intervention group
Group type: EXPERIMENTAL
Intervention: ampicillin
Number of subjects: 50
Study 8495702 — intervention group
Group type: EXPERIMENTAL
Intervention: trimethoprim/sulphamethoxazole
Number of subjects: 50
Study 8495702 — intervention group
Group type: COMPARATOR
Intervention: placebo I
Number of subjects: 50
Study 8495702 — intervention group
Group type: COMPARATOR
Intervention: placebo II
Number of subjects: 50
Study 8495702 — intervention group
Group type: EXPERIMENTAL
Intervention: antibiotic (1 day)
Number of subjects: 50
Study 8495702 — intervention group
Group type: COMPARATOR
Intervention: placebo (1 day)
Number of subjects: 50
Study 8495702 — intervention group
Group type: EXPERIMENTAL
Intervention: antibiotic (3 days)
Number of subjects: 50
Study 8495702 — intervention group
Group type: COMPARATOR
Intervention: placebo (3 days)
Number of subjects: 50
Study 3352775 — intervention group
Group type: EXPERIMENTAL
Intervention: Total nodal irradiation (TNI)
Number of subjects: 257
Study 3352775 — intervention group
Group type: COMPARATOR
Intervention: Combined sequence of mantle irradiation with mechlorethamine, vincristine, procarbazine, and prednisone (MOPP X 3-mantle irradiation-MOPP X 3; 3M)
Number of subjects: 257
Study 31829432 — intervention group
Group type: EXPERIMENTAL
Intervention: Structural nested RMTL model (SNRMTLM)
Number of subjects: 0
Study 31829432 — intervention group
Group type: COMPARATOR
Intervention: Conventional intention-to-treat analysis
Number of subjects: 0
Study 31829432 — intervention group
Group type: COMPARATOR
Intervention: Per-protocol analysis
Number of subjects: 0
Study 30035621 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamins and minerals supplementation
Number of subjects: 0
Study 28724581 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-dose gadolinium administration during MRI scans
Number of subjects: 75
Study 26142300 — intervention group
Group type: EXPERIMENTAL
Intervention: Managed Ventricular Pacing (MVP)
Number of subjects: 605
Study 26142300 — intervention group
Group type: COMPARATOR
Intervention: Standard Dual-Chamber Pacing
Number of subjects: 605
Study 22702228 — intervention group
Group type: EXPERIMENTAL
Intervention: Stopping smoking for 2 weeks
Number of subjects: 1126
Study 22702228 — intervention group
Group type: COMPARATOR
Intervention: Continuing to smoke for 2 weeks
Number of subjects: 1126
Study 21981459 — intervention group
Group type: EXPERIMENTAL
Intervention: BFR walk group
Number of subjects: 16
Study 21981459 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study 18720671 — intervention group
Group type: EXPERIMENTAL
Intervention: Formaldehyde ingestion
Number of subjects: 5
Study 18720671 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 5
Study 16582056 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT), 22 sessions
Number of subjects: 253
Study 16582056 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 253
Study 12655445 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydration solution with 100 mEq/l sodium (regimen B)
Number of subjects: 30
Study 12655445 — intervention group
Group type: COMPARATOR
Intervention: Hydration solution with 70 mEq/l sodium (regimen A)
Number of subjects: 30
Study 12655445 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 30
Study 11078293 — intervention group
Group type: EXPERIMENTAL
Intervention: Electron Beam Computed Tomography (EBCT)
Number of subjects: 207
Study 11078293 — intervention group
Group type: COMPARATOR
Intervention: Exercise Treadmill Testing (ETT)
Number of subjects: 207
Study 8975683 — intervention group
Group type: EXPERIMENTAL
Intervention: Heightened awareness of theological beliefs
Number of subjects: 0
Study 8975683 — intervention group
Group type: COMPARATOR
Intervention: Anthropomorphic God concept
Number of subjects: 0
Study 1596307 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate
Number of subjects: 100
Study 1596307 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 6726650 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone (0.5, 1.0, or 2.0 times their regular maintenance dose of 40-60 mg)
Number of subjects: 5
Study 6726650 — intervention group
Group type: COMPARATOR
Intervention: Dextromethorphan (placebo control)
Number of subjects: 5
Study 30816244 — intervention group
Group type: EXPERIMENTAL
Intervention: One night of total sleep deprivation
Number of subjects: 183
Study 30816244 — intervention group
Group type: COMPARATOR
Intervention: Fourth night with 8-9 hours in bed (control)
Number of subjects: 183
Study 29489895 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS (2 mA)
Number of subjects: 24
Study 29489895 — intervention group
Group type: COMPARATOR
Intervention: Sham (placebo)
Number of subjects: 24
Study 27009101 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon nanoparticles (CNPs) injected into the subserosa of the stomach around the tumor before gastrectomy
Number of subjects: 30
Study 27009101 — intervention group
Group type: COMPARATOR
Intervention: Control group (no coloring material)
Number of subjects: 30
Study 24263660 — intervention group
Group type: EXPERIMENTAL
Intervention: with mouthpiece (MP)
Number of subjects: 21
Study 24263660 — intervention group
Group type: COMPARATOR
Intervention: without mouthpiece (noMP)
Number of subjects: 21
Study 23273042 — intervention group
Group type: EXPERIMENTAL
Intervention: Deprexis web-based psychological treatment
Number of subjects: 80
Study 23273042 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 80
Study 20464803 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana
Number of subjects: 85
Study 20464803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 17980884 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe (10mg/day)
Number of subjects: 72
Study 17980884 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/day)
Number of subjects: 72
Study 17980884 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ezetimibe and simvastatin
Number of subjects: 72
Study 17980884 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 72
Study 16226024 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol via Easyhaler
Number of subjects: 33
Study 16226024 — intervention group
Group type: COMPARATOR
Intervention: Formoterol via Aerolizer
Number of subjects: 33
Study 16226024 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirometry (both devices)
Number of subjects: 33
Study 12351592 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial lozenge (Bacitracin, Clotrimazole, Gentamicin)
Number of subjects: 137
Study 12351592 — intervention group
Group type: COMPARATOR
Intervention: Placebo lozenge
Number of subjects: 137
Study 10399232 — intervention group
Group type: EXPERIMENTAL
Intervention: Structum and ibuprofen (1200 mg/day) for 6 months
Number of subjects: 100
Study 10399232 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen only
Number of subjects: 100
Study 7480566 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (nonselective adrenoceptor antagonist)
Number of subjects: 0
Study 7480566 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 0
Study 1979499 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopaminergic antidepressant drugs
Number of subjects: 0
Study 1979499 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone treatment
Number of subjects: 0
Study 1979499 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (gonadotropins, testosterone)
Number of subjects: 0
Study 1979499 — intervention group
Group type: EXPERIMENTAL
Intervention: DA agonist and/or 5‐HT antagonist drugs
Number of subjects: 0
Study 6280229 — intervention group
Group type: EXPERIMENTAL
Intervention: KMT with polychemotherapy
Number of subjects: 38
Study 6280229 — intervention group
Group type: EXPERIMENTAL
Intervention: KMT with radiotherapy
Number of subjects: 38
Study 30835152 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive tianeptine 37.5 mg/day
Number of subjects: 161
Study 30835152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study 28634889 — intervention group
Group type: EXPERIMENTAL
Intervention: Airflow
Number of subjects: 82
Study 28634889 — intervention group
Group type: EXPERIMENTAL
Intervention: Seat vibration
Number of subjects: 82
Study 28634889 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined airflow and vibration
Number of subjects: 82
Study 28634889 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 82
Study 25154734 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-ablative fractional laser treatment (three monthly treatments)
Number of subjects: 20
Study 25154734 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-ablative fractional laser treatment
Number of subjects: 20
Study 25154734 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 20
Study 22560940 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal protein diet
Number of subjects: 11116
Study 22560940 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal protein diet among ever smokers
Number of subjects: 11116
Study 21117975 — intervention group
Group type: EXPERIMENTAL
Intervention: Violent video game
Number of subjects: 0
Study 21117975 — intervention group
Group type: COMPARATOR
Intervention: Nonviolent video game
Number of subjects: 0
Study 21117975 — intervention group
Group type: EXPERIMENTAL
Intervention: Violent video game (females)
Number of subjects: 0
Study 21117975 — intervention group
Group type: EXPERIMENTAL
Intervention: Violent video game (males)
Number of subjects: 0
Study 19724023 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe (10 mg/day) plus Orlistat (120 mg, 3 times a day with meals)
Number of subjects: 30
Study 19724023 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe (10 mg/day) plus Rimonabant (20 mg/day)
Number of subjects: 30
Study 19724023 — intervention group
Group type: COMPARATOR
Intervention: Ezetimibe plus Orlistat
Number of subjects: 30
Study 19724023 — intervention group
Group type: COMPARATOR
Intervention: Ezetimibe plus Rimonabant
Number of subjects: 30
Study 19724023 — intervention group
Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 30
Study 17634977 — intervention group
Group type: EXPERIMENTAL
Intervention: Five asymptotic interval estimators for the proportion ratio (PR) including WLS estimator, Mantel-Haenszel type weight, Fieller's Theorem with WLS optimal weight, Fieller's Theorem with randomization-based optimal weight, and stratified two-sample proportion test with optimal weight.
Number of subjects: 0
Study 15631659 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol (600 mg/day) or Stanazol (6 mg/day) and ATRA (10 mg/day) for at least 3 months
Number of subjects: 55
Study 11531038 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training programme (13 weeks, twice a week, 1 hour per session)
Number of subjects: 33
Study 11531038 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 33
Study 9603640 — intervention group
Group type: EXPERIMENTAL
Intervention: EPx4 cycles (etoposide 120 mg/m2 i.v. days 1-3 and cisplatin 80 mg/m2 day 1)
Number of subjects: 70
Study 9603640 — intervention group
Group type: COMPARATOR
Intervention: EPx6 cycles (etoposide 120 mg/m2 i.v. days 1-3 and cisplatin 80 mg/m2 day 1)
Number of subjects: 70
Study 9603640 — intervention group
Group type: EXPERIMENTAL
Intervention: EPx4 cycles
Number of subjects: 70
Study 7825195 — intervention group
Group type: EXPERIMENTAL
Intervention: Suicide intervention classes
Number of subjects: 0
Study 7825195 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 3420161 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 30 mg 3 times daily
Number of subjects: 10
Study 3420161 — intervention group
Group type: COMPARATOR
Intervention: Control (drug-free)
Number of subjects: 10
Study 30296633 — intervention group
Group type: EXPERIMENTAL
Intervention: Involuntary treatment
Number of subjects: 1194
Study 30296633 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-consensual care
Number of subjects: 1194
Study 30296633 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotropic drugs
Number of subjects: 1194
Study 30296633 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical restraints
Number of subjects: 1194
Study 30296633 — intervention group
Group type: EXPERIMENTAL
Intervention: Dependency for activities of daily life
Number of subjects: 1194
Study 30296633 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive impairment
Number of subjects: 1194
Study 30296633 — intervention group
Group type: EXPERIMENTAL
Intervention: Informal caregiver burden
Number of subjects: 1194
Study 30296633 — intervention group
Group type: EXPERIMENTAL
Intervention: Aging
Number of subjects: 1194
Study 30296633 — intervention group
Group type: EXPERIMENTAL
Intervention: Requests for involuntary treatment
Number of subjects: 1194
Study 30296633 — intervention group
Group type: EXPERIMENTAL
Intervention: Application of involuntary treatment
Number of subjects: 1194
Study 27263325 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + MM
Number of subjects: 60
Study 27263325 — intervention group
Group type: COMPARATOR
Intervention: SRP
Number of subjects: 60
Study 24811759 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial invitation by mail
Number of subjects: 3777
Study 24811759 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial invitation by phone
Number of subjects: 3777
Study 24811759 — intervention group
Group type: EXPERIMENTAL
Intervention: Recall by appointment with a specialist practitioner
Number of subjects: 3777
Study 24811759 — intervention group
Group type: COMPARATOR
Intervention: Mail recall
Number of subjects: 3777
Study 24811759 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face counselling with GP
Number of subjects: 3777
Study 21948957 — intervention group
Group type: EXPERIMENTAL
Intervention: APT Hotline
Number of subjects: 0
Study 21948957 — intervention group
Group type: EXPERIMENTAL
Intervention: APT Pharmacy
Number of subjects: 0
Study 21948957 — intervention group
Group type: COMPARATOR
Intervention: Routine PN
Number of subjects: 0
Study 20103545 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (300 mg at 90 minutes preoperatively and 150 mg at 12 and 24 hours postoperatively)
Number of subjects: 40
Study 20103545 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 20103545 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 40
Study 18211256 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstetric gel use
Number of subjects: 251
Study 18211256 — intervention group
Group type: COMPARATOR
Intervention: No obstetric gel use (Control)
Number of subjects: 251
Study 17507385 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed speculum group
Number of subjects: 45
Study 17507385 — intervention group
Group type: COMPARATOR
Intervention: Open speculum group
Number of subjects: 45
Study 12860574 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigued respondents (n=3528)
Number of subjects: 7162
Study 12860574 — intervention group
Group type: COMPARATOR
Intervention: Nonfatigued respondents (n=3634)
Number of subjects: 7162
Study 12860574 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 7162
Study 12860574 — intervention group
Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 7162
Study 10852317 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Number of subjects: 2649
Study 9356796 — intervention group
Group type: EXPERIMENTAL
Intervention: clemastine fumarate
Number of subjects: 403
Study 9356796 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 403
Study 8402658 — intervention group
Group type: EXPERIMENTAL
Intervention: 4‐HPR 200 mg/daily
Number of subjects: 60
Study 8402658 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 60
Study 2876722 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol (2.5-40 mg)
Number of subjects: 36
Study 2876722 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (40 and 80 mg)
Number of subjects: 36
Study 2876722 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (50 and 100 mg)
Number of subjects: 36
Study 2876722 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (50 and 100 mg)
Number of subjects: 36
Study 29320670 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy
Number of subjects: 1050
Study 29320670 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 1050
Study 29320670 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotherapy
Number of subjects: 1050
Study 29320670 — intervention group
Group type: EXPERIMENTAL
Intervention: E-cigarettes
Number of subjects: 1050
Study 29320670 — intervention group
Group type: EXPERIMENTAL
Intervention: E-cigarettes consideration
Number of subjects: 1050
Study 29320670 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirometry testing
Number of subjects: 1050
Study 29320670 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis of COPD
Number of subjects: 1050
Study 29320670 — intervention group
Group type: EXPERIMENTAL
Intervention: Misdiagnosis of COPD
Number of subjects: 1050
Study 26994397 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy for ultra-high risk (CBTuhr)
Number of subjects: 196
Study 26994397 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 196
Study 26859020 — intervention group
Group type: EXPERIMENTAL
Intervention: Honey
Number of subjects: 145
Study 26859020 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 145
Study 26859020 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study 22116378 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine hydrochloride (10 mg) combined with virtual reality exposure therapy (VRET)
Number of subjects: 67
Study 22116378 — intervention group
Group type: COMPARATOR
Intervention: Placebo combined with virtual reality exposure therapy (VRET)
Number of subjects: 67
Study 20181126 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrequent modified images (p = .2)
Number of subjects: 0
Study 20181126 — intervention group
Group type: COMPARATOR
Intervention: Frequent unmodified images (p = .8)
Number of subjects: 0
Study 18640889 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors (AI) such as anastrozole or letrozole for 5 years
Number of subjects: 0
Study 18640889 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential approach of tamoxifen for 2-3 years followed by anastrozole or exemestane for 2-3 years
Number of subjects: 0
Study 18640889 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole for up to 4-5 years after completing 5 years of tamoxifen in node-positive disease
Number of subjects: 0
Study 15875763 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalometric analysis of soft tissues
Number of subjects: 33
Study 15875763 — intervention group
Group type: COMPARATOR
Intervention: Conventional dental evaluations
Number of subjects: 33
Study 12861539 — intervention group
Group type: EXPERIMENTAL
Intervention: In-line projection screen
Number of subjects: 108
Study 12861539 — intervention group
Group type: COMPARATOR
Intervention: Overhead monitor
Number of subjects: 108
Study 10100179 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive preparation (20 micrograms of ethinyl estradiol plus 0.15 mg desogestrel)
Number of subjects: 3
Study 10100179 — intervention group
Group type: EXPERIMENTAL
Intervention: Perimenopausal OC-treated women
Number of subjects: 3
Study 10100179 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy, normally menstruating women)
Number of subjects: 3
Study 8684872 — intervention group
Group type: EXPERIMENTAL
Intervention: PFP-2 vaccine
Number of subjects: 34
Study 8684872 — intervention group
Group type: COMPARATOR
Intervention: Saline vaccine (control)
Number of subjects: 34